Startups

Senior Manager, Trial Awareness & Recruitment

Rapport Therapeutics · 99 High Street, Suite 2100 , Boston, MA 02110 · On-site

← All jobs
About Rapport Therapeutics

Precision medicines to match the complexity of the human brain. Backed by Third Rock Ventures.

About the role

As our Senior Manager, Trial Awareness & Recruitment, you’ll help get the right patients into the right trials. You’ll drive recruitment and patient engagement across our clinical portfolio, partnering with Clinical Ops, Medical Affairs, and external vendors to keep enrollment moving and build scalable recruitment programs as we grow. Found on 1752vc Careers, the job board for startup and VC roles.

What they're looking for

  • Bachelor's degree required
  • 6-8 years of experience in clinical trial recruitment, patient engagement, trial awareness, or a related function within the biotech or pharmaceutical industry
  • Experience working within a small biotech or clinical-stage company strongly preferred
  • Track record executing patient recruitment strategies that have positively impacted enrollment timelines
  • Experience partnering with Clinical Operations, Medical Affairs, and cross-functional stakeholders
  • Working knowledge of patient recruitment vendors, advocacy organizations, and digital outreach strategies
More about this role

When our people share why they joined Rapport and love it here, it comes down to three things: the science, the mission, and the team. At Rapport, we’re driven by a passion for developing precision neuromedicines with the potential for fewer side effects, enabling patients and their families to enjoy healthier, more fulfilling lives. And we’re doing this with extraordinary science and awesome people (affectionately called Rapptors).

Our innovative scientific platform is centered on Receptor Associate Proteins (RAPs). RAPs are a component of neuronal receptor complexes, which play a crucial role in regulating receptor assembly and function. This precision approach has the potential to revolutionize the development of small molecule therapies. We are excited about the potential of our lead program, RAP-219. Our first indication targets focal epilepsy with additional clinical trials in primary generalized tonic-clonic seizures (PGTCS) and bipolar disorder.

The strength of Rapport comes from our Rapptors – who are united by our mission to improve patients lives. We bring the heart and hustle to advance our science forward, always staying true to our core values. We hope you’re as...

Read the full posting on Rapport Therapeutics's site ↗

Clinical Operations

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.